DiaSys assay for cardiovascular disease, stroke Lp-PLA2 biomarker
Lp-PLA2 (Lipoprotein-associated phospholipase A2) is an inflammatory enzyme expressed in atherosclerotic plaques. It is determined as an additional and vascular specific biomarker to predict risk for cardiovascular disease and stroke.
Guidelines from four major international societies (European Society of Cardiology, American College of Cardiology, American Heart Association and American Society of Endocrinology) recommend measurement of Lp-PLA2 for risk stratification in asymptomatic adults.
The liquid-stable, enzymatic DiaSys test Lp PLA2 FS, which determines the activity of the enzyme Lp-PLA2 in serum and plasma, has been available for many years. The assay covers a wide measuring range up to 2000 U/L, offers outstanding onboard and calibration stability and shows excellent precision at clinical cut-off levels. No significant interferences are observed by endogenous compounds; frequently used drugs for dyslipidemia and atherosclerosis do not affect the test.
As no reference method or material for Lp-PLA2 has been available, DiaSys applied the scientifically proven traceability to the reagent specific molar extinction coefficient of 4 nitrophenol to their parameter Lp-PLA2 FS. By this proceeding, DiaSys Lp-PLA2 FS is directly traceable to the Lp-PLA2 reaction product 4-nitrophenol.
Supplier: DiaSys Diagnostic Systems GmbH
Website: https://www.diasys-diagnostics.com
